RESEARKA

In advanced atherosclerotic Apoe-/- mouse models, does ABT-263 senolytic treatment support a narrow warning that senescent-cell clearance can reduce smooth-muscle-associated plaque features while simultaneously increasing endothelial-to-mesenchymal transition and mortality risk, and should this signal be framed as a therapeutic-window concern rather than as evidence that senolytics are broadly harmful or broadly beneficial?

Citation Support

• source_1 Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
• source_2 Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts
• source_3 Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence
• source_4 Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice